Sanofi India Q1 Results Review — Strong Earnings; Focus On Rx: Centrum Broking

Centrum Broking Report

Sanofi India Ltd.’s Q1 CY23 result beats our estimates. Revenue came at Rs 7.4 billion up by 4% YoY (down by 10% QoQ), mainly led by volume pick-up in core brands, post the divestment of Universal Medicare business and two brands Soframycin plus Sofradex.

Gross margin improved by ~103 basis points YoY mainly driven by a favorable mix at 58.6%. Lower overhead cost resulted Ebitda margin improvement by 370 bps YoY at 31.2%.

The quarter had an exceptional item on profit on sale of property Rs 255 million and separation cost related to demerger of Rs 77 million, adjusted to this the profit after tax increased by 44% YoY to Rs 1.7 billion.

Going forward, earnings to reflect the impact of Lantus came under National List of Essential Medicines. However, management assured that no major impact earnings.

Sanofi India to de-merge its consumer business to make it as a separate entity resulting into more focus on individual businesses and value unlocking for the shareholders.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.